Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.49 |
| ▸ | GBA1 | P04062 | 8/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | GBA2 | Q9HCG7 | 11/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | UGCG | Q16739 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590808 | 1.00 | S1PR1 (0.49) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| Methane SCHEMBL6600535 | 0.98 | S1PR1 (0.48) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| SCHEMBL2850065 | 0.98 | S1PR1 (0.47) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| SCHEMBL4229106 | 0.92 | GBA2 (0.46) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| SCHEMBL3265496 | 0.92 | S1PR1 (0.50) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| Pyrrolidine SCHEMBL4393172 | 0.89 | GBA1 (0.43) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| SCHEMBL28123990 | 0.86 | GBA2 (0.47) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| SCHEMBL27675556 | 0.84 | GBA1 (0.43) | S1PR1S1PR3S1PR5GBA1GAA | |
| SCHEMBL19126196 | 0.79 | CXCR4 (0.50) | S1PR1S1PR3S1PR5GBA1S1PR4 | |
| SCHEMBL14079463 | 0.79 | CXCR4 (0.50) | S1PR1S1PR3S1PR5GBA1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682504-B1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7741340-B2 | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20050130972-A1 | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | GBA1, GAA, GBA2 | S1PR1 905/4885S1PR3 947/4885S1PR5 1591/4885 |
| US-20050130972-A1 | Hydroxy piperidine derivatives to treat gaucher disease | GBA1, GAA, GBA2 | S1PR1 905/4885S1PR3 947/4885S1PR5 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.